Cost-free pharmacotherapy in smokers with TIA or stroke: QUIT-MED randomised controlled trial. Issue 8 (5th August 2022)

• Record Type: Journal Article
• Authors: Reid, Robert; Papadakis, Sophia; Gocan, Sophia; Bourgoin, Aline; Laplante, Mary Ann; Armstrong, Ashley; Aitken, Debbie; Sahlas, Demetrios; Stotts, Grant; Cotie, Lisa; Mullen, Kerri-Anne; Pipe, Andrew; Mir, Hassan; Sharma, Mukul
• Is Part Of: BMJ open. Volume 12:Issue 8(2022)
• Publication Date: 2022-08-05
• Subjects: STROKE MEDICINE -- Stroke -- Clinical trials; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-050403
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objective: To examine whether cost-free (CF) smoking cessation medication was more effective than a prescription for cessation medication in patients after transient ischaemic attack (TIA) or stroke. Design: Two-site randomised trial. Setting: Stroke prevention clinics (SPCs) in Ontario, Canada. Participants: Smokers with TIA or stroke, willing to quit smoking. Intervention: Smoking status was assessed in SPC attendees. Smokers were advised to quit smoking and received recommendations for cessation medication and counselling. Consenting participants were randomly assigned (1:1) to either a CF medication group or a prescription-only (Rx) group. CF participants immediately received a 12-week supply of cessation medication. Rx participants were given a prescription for 12 weeks of cessation medication. Follow-up counselling was provided for 26 weeks. Main outcome: The primary outcome was 40-week continuous abstinence verified using a carbon monoxide breath test at 52-week follow-up. Secondary outcomes included abstinence at intermediate timepoints, medication adherence and serious adverse events. Results: Hundred and ninety-four participants were randomised and 131 (67.5%) completed the trial. The 40-week continuous abstinence rate at 52-week follow-up was 15.5% in the CF group versus 14.0% in the Rx group (OR=1.13; 95% CI 0.51 to 2.53). The 14-week continuous abstinence rate at 26-week follow-up was 18.6% in the CF group versus 16.8% in the Rx group (OR=1.20; 95% CI 0.56 to 2.55). Seven-day point-prevalence abstinence at 12 weeks was 38.1% in the CF group versus 26.9% in the Rx group (OR=1.76; 95% CI 0.94 to 3.28). Medication adherence was higher in the CF group versus the Rx group (47.4%±41.2% vs 25.5±36.8%, p<0.001). Serious adverse events occurred in 11.1% of participants and were unrelated to treatment. Conclusions: Our findings were inconclusive; we failed to meet our recruitment target and the effect size was smaller than anticipated. CF medication improved medication adherence. Trial registration number: NCT00962988 ; ClinicalTrials.gov Identifier.